GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility
Trial Timeline
Mar 24, 2023 → Jan 29, 2024
NCT ID
NCT06091436About GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone
GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone is a phase 3 stage product being developed by Sun Pharmaceutical for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT06091436. Target conditions include Infertility.
What happened to similar drugs?
16 of 20 similar drugs in Infertility were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06091436 | Phase 3 | Completed |
Competing Products
20 competing products in Infertility